Clinical trials
Neuroendocrine Tumors clinical trials
Below are recruiting neuroendocrine tumors clinical trials, each written for real people, not researchers. We’re tracking 173 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT00923026Enrolling by invitation
Follow-up for adults previously treated in NCI surgery studies
This study asks people age 18+ who were previously treated on certain NCI Surgery Branch (NCI-SB) studies to come back for follow-up. It helps researchers understand how patients do over time after those earlier treatments, including some gene therapy studies.
Bethesda, MarylandAges 18 years+ - NCT07439757Recruiting
Using AI to Guide Care for Pancreatic Conditions
This study uses artificial intelligence (AI) to help doctors make better decisions for people with suspected pancreatic conditions. If you are already getting a special CT scan, the AI will analyze the images to see if it can improve diagnosis and treatment planning.
ShanghaiAges 18–80 - NCT07463625Recruiting
PET scan for finding ACTH-secreting pituitary tumors
This trial tests a special PET scan using a tracer called FET to locate tiny ACTH-producing pituitary tumors (microadenomas) causing Cushing's disease. It might help guide surgery by identifying exactly where the tumor is in the gland.
BronAges 18 years+ - NCT07463872Recruiting
Managing pancreatic cysts with AI and EUS data
This study uses artificial intelligence to look at EUS images and other information to better understand and manage pancreatic cysts. It aims to help doctors tell different types of cysts apart so they can choose the best treatment for you.
Wuhan, HubeiAges 18 years+ - NCT07554560Recruiting
Nutrition Support for Pancreatic Cancer Patients
This study tests a nutrition intervention for people with pancreatic cancer who are having trouble eating or absorbing nutrients. The goal is to help patients maintain strength and improve their quality of life during cancer treatment.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05160480Enrolling by invitation
Total-body PET scan using FDA-approved tracers for prostate or NET cancer
This pilot study tests a total-body PET scan with approved tracer medicines to help detect cancer spread in people with suspected metastatic prostate cancer or certain neuroendocrine tumors (NETs). You may be able to join if recent scans already suggest metastasis and you can safely complete the scan timing and positioning.
Sacramento, CaliforniaAges 18 years+ - NCT06717243Recruiting
Study on gene markers in lung cancer for treatment resistance
This study looks at genetic markers in two types of lung cancer (small cell and large cell neuroendocrine) to understand why some tumors stop responding to a standard treatment that combines chemotherapy with immunotherapy. If you have one of these cancers and are about to start this treatment, you may be able to join.
New York, New YorkAges 18–85 - NCT07121998Recruiting
Study of resistance to alkylating chemotherapy in endocrine tumors
This study looks at why some endocrine tumors (tumors in hormone-making glands) stop responding to a specific type of chemotherapy called alkylating agents. Researchers will collect tissue samples to understand how the tumor changes and why the medicine stops working.
UppsalaAges 18 years+ - NCT07284589RecruitingPhase 2
Ultralow dose pet scan for certain tumors
This trial tests a new way to take PET scan pictures using a very low amount of a radioactive tracer that targets a protein called SSTR2. It is designed to see if these scans can work well while reducing radiation exposure for patients with certain types of tumors.
Englewood, New JerseyAges 18–120 - NCT07542158Enrolling by invitationPhase 2
Ultra-Low Radiation PET Imaging Study for Brain Scanning
This study tests a new way to take brain imaging scans (PET scans) using a very small amount of radioactive tracer. Researchers want to see if they can get clear pictures of your brain while reducing your radiation exposure compared to standard scans.
Englewood, New JerseyAges 18–120 - NCT07174583RecruitingPhase 1/Phase 2
Study of IDE849 for DLL3-positive cancers like SCLC
This trial tests a new drug called IDE849 for cancers that make a protein called DLL3, including small cell lung cancer and some neuroendocrine tumors. It is for people whose cancer has progressed after standard treatments, and may be given alone or combined with other drugs like durvalumab or IDE161.
Denver, ColoradoAges 18 years+ - NCT04723095Recruiting
Cervical neuroendocrine cancer registry for past and present patients
This study builds a registry (a secure database) of people who have had cervical neuroendocrine cancer, including small cell or large cell types. It helps researchers learn more about these cancers and may improve future care and research planning.
Houston, TexasAges Any age - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Birmingham, AlabamaAges 18 years+ - NCT06683846RecruitingPhase 2
Ivonescimab for advanced rare tumors: a safety & early-efficacy study
This trial tests a drug called ivonescimab in people with advanced, rare tumor types that have spread (stage IV). The goal is to see if the drug is safe and whether it can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05969860RecruitingPhase 2
Home cancer treatment vs clinic treatment for advanced cancer
This Phase 2 trial compares giving certain standard cancer infusions at home versus in a clinic. It may help people avoid clinic visits while still receiving the same cancer treatment safely.
Jacksonville, FloridaAges 18 years+ - NCT06161532RecruitingPhase 2
Sacituzumab govitecan with or without atezolizumab for rare GU cancers
This trial is testing a drug called sacituzumab govitecan, sometimes combined with atezolizumab (an immunotherapy), for rare cancers of the bladder, urinary tract, kidney, or penis. The goal is to see if these treatments work well for people whose cancers have not responded to other options.
Bethesda, MarylandAges 18–120 - NCT07006727RecruitingPhase 1
Targeted radiation therapy for DLL3-positive advanced cancers
This study tests a new targeted radiation therapy (called [225Ac]Ac-ETN029) for people with advanced cancers that have a protein called DLL3 on their cells. The treatment is designed to deliver radiation directly to cancer cells, and the goal is to see if it is safe and effective.
Iowa City, IowaAges 18–100 - NCT07517198RecruitingPhase 1
EXS74539 Study for Advanced Solid Tumors
This is an early-stage study testing a new cancer drug called EXS74539 to find the right dose and see how well it works in people with various advanced solid tumors. The drug may help patients whose cancers have stopped responding to standard treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT06424665RecruitingPhase 1
Study of FZ-AD005 for advanced solid tumors
This trial tests a new drug called FZ-AD005 for people with advanced solid tumors, especially small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC). It may help if standard treatments are no longer working.
Changsha, HunanAges 18–75 - NCT06043193Recruiting
Quality of life study for patients with neuroendocrine tumors getting internal radiation therapy
This study looks at how internal radiation therapy (RIV) affects quality of life in people with neuroendocrine tumors. It aims to understand how well patients tolerate this treatment and how it impacts daily life.
Saint-Priest-en-Jarez, Saint-EtienneAges 18 years+ - NCT06333314RecruitingPhase 2
Dostarlimab for advanced dMMR/MSI cancers (not colorectal or endometrial)
This trial tests a drug called dostarlimab for people with certain advanced cancers that have a specific genetic feature (dMMR/MSI-H). The goal is to see if it helps shrink or control the cancer in people who haven't had other treatments yet.
AngersAges 18 years+ - NCT01416714Recruiting
Tissue sample collection during cancer surgery or biopsy
This study is collecting tissue samples from people with certain cancers while they have surgery or a biopsy. It may help researchers learn more about these cancers and improve future diagnosis and treatment.
Chicago, IllinoisAges Any age - NCT06607692RecruitingPhase 1/Phase 2
LuPARPed: Targeted radiation plus olaparib for certain childhood cancers
This trial tests a combination of a radioactive drug (Lutathera) and a targeted pill (olaparib) for children and teens whose solid tumors have come back or not responded to treatment and show high levels of a specific receptor (SSTR) on scans. The goal is to see if this two-drug approach can shrink tumors or stop them from growing.
Boadilla del Monte, MadridAges 3 years+ - NCT06062745RecruitingPhase 1
PET scan study for prostate cancer with low PSMA or neuroendocrine features
This study tests a special PET scan (fluciclovine) to see if it can better detect prostate cancer that has low PSMA levels or has changed to a neuroendocrine type. It may help find tumors that standard PSMA scans miss.
Boston, MassachusettsAges 18 years+
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for neuroendocrine tumors?
- Yes. Clin2 currently lists 173 recruiting neuroendocrine tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a neuroendocrine tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a neuroendocrine tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.